AI in Drug Discovery Market Size, Trends, Scope, Demand, Opportunity, and Forecast by 2033

The global AI in drug discovery market size reached USD 1.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 14.0 Billion by 2033, exhibiting a growth rate (CAGR) of 23.17% during 2025-2033. Oncology dominates the market driven by the rising cancer prevalence drives demand for AI-based tools to identify new cancer therapies and personalize treatment approaches.

The AI in drug discovery market in 2025 is growing as pharma, biotechs, and research institutes embrace machine learning to accelerate R&D and reduce costs. The market consists of algorithms, platforms, cloud infrastructure, curated data sets, and services that inform target identification, molecule design, safety prediction, and clinical success optimization. The mission is straightforward: discover better drugs faster with greater confidence and reduced attrition.

What the Market Covers

AI solutions now enable the entire discovery pipeline, from target discovery and hit finding to lead optimisation and selection of preclinical candidates. Firms are combining AI with lab automation, high-content screening, and cloud-based data lakes so that models can learn iteratively from experiments. Contract research organisations are including AI modules within their services, and large pharma is embarking on long-term alliances to co-develop assets and share risk.

Latest Trends in AI in Drug Discovery Market

One of the key trends is growth in foundation and generative models that design de novo small molecules and optimize protein sequences. Multimodal AI integrates chemistry, biology, imaging, and omics data to enhance potency, selectivity, and ADMET predictions. In silico screening in bulk is replacing early wet-lab cycles, while active learning loops choose the most informative experiments to cut cycle times. Large language models are being adapted to scientific text and lab protocols, helping teams generate hypotheses, design assays, and document methods.

Another critical change is the trend toward precision discovery. AI connects patient-level genomics and real-world evidence with disease biology to rank targets and risk-stratify trial populations. It enables biomarker-driven programmes, drug repurposing, and rare-disease programmes in which data are limited. Synthetic data generation and federated learning are emerging to overcome privacy and data-sharing obstacles between institutions.

Key Market Drivers

Market is fueled by necessity for enhancing R&D productivity, controlling increased development expenses, and reducing time-to-IND. Improved compute, scalable cloud infrastructure, and growing public datasets are reducing barriers to entry. Regulators are providing clarification on model validation and data management, raising confidence in AI-fueled decisions. Investment flows continue to be robust, with partnerships that link milestone payments to AI-driven candidates and quantifiable time savings.

Market Outlook

Challenges persist with data quality, bias, reproducibility, and explainability. Firms are meeting compliance and IP requirements with strong MLOps, model audits, and FAIR data practices. Generally, the AI in drug discovery market in 2025 is characterized by generative design, multimodal integration, and value-based partnerships. As algorithms continue to mature and evidence mounts, AI becomes an integral driver of discovery, enhancing success rates and delivering new treatments to patients faster.

AI in Drug Discovery Market Report Segmentation:

Breakup by Offering:

• Software
• Services

Breakup by Application:

• Preclinical Testing
• Drug Optimization and Repurposing
• Target Identification
• Candidate Screening
• Others

Breakup by Therapeutic Area:

• Oncology
• Neurodegenerative Diseases
• Cardiovascular Diseases
• Metabolic Diseases
• Others

Breakup by End User:

• Pharmaceutical and Biotechnology Companies
• Contract Research Organizations (CROs)
• Research Centers and Academic Institutes

Get your Sample of AI in Drug Discovery Market Insights for Free: https://www.imarcgroup.com/ai-in-drug-discovery-market/requestsample

Who are the key players operating in the industry?

The report covers the major market players including:

• Aria Pharmaceuticals Inc.
• Atomwise Inc.
• Benevolent AI
• BioSymetrics Inc
• BPGbio Inc
• Deep Genomics
• Envisagenics
• Euretos
• Evaxion Biotech A/S
• Exscientia
• Insilico Medicine
• NVIDIA Corporation
• Okwin Inc
• XtalPi Inc

Breakup by Region:

• North America
• Asia-Pacific
• Europe
• Latin America
• Middle East and Africa

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services.

IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact US:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: [email protected]

Tel No:(D) +91 120 433 0800

United States: +1-201971-6302